Skip to main content

Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.

Ørntoft MW, Jensen SØ, Øgaard N, Henriksen TV, Ferm L, Christensen IJ, Reinert T, Larsen OH, Nielsen HJ, Andersen CL

Publication: Int J Cancer (2021) • Vol 148 • Page 1665-1675PMID: 33320961View on PubMed

Purpose

This paper compared cell-free DNA (cfDNA) levels in plasma stored for <5 years and ≥5 years and investigated the association between cfDNA levels and patient age, gender, smoking status, body mass index (BMI), chronic disease, alcohol consumption, and colonoscopy preparation on median cfDNA levels. The effects of cancer stage and metastasis on cfDNA levels in patients with colorectal carcinoma (CRC) was also investigated.

Conclusion

Plasma stored for ≥5 years had significantly lower levels of cfDNA than plasma stored for <5 years. Multivariate regression analysis showed elevated cfDNA levels were associated with undergoing colonoscopy preparation, patient age, BMI, and increased number of chronic diseases as well as diagnosis with diabetes, heart disease, hypertension, IBD, pulmonary disease, or rheumatoid arthritis. Reduced cfDNA levels were associated with smoking. There was a non-significant trend toward higher cfDNA levels in males than females but there was no effect of number of units of alcohol consumed per week. Patients with CRC had significantly higher cfDNA levels than those without cancer but, when broken down by cancer stage, the difference was only significant for those with stage IV CRC. cfDNA levels were higher in patients with metastatic CRC than those without metastasis and increased with tumor size. Overall survival was negatively associated with cfDNA levels >90% of the age-stratified reference after normalization for gender, BMI, smoking status, alcohol consumption, chronic diseases, and CRC stage. In patients without cancer, overall survival was also negatively associated with patient age, smoking, and presence of three or more chronic diseases. In patients with CRC, overall survival was negatively associated with stage III or IV disease and age.

Studies (1)

Purpose

This study compared cfDNA levels in plasma stored for <5 years and ≥5 years and investigated the association between cfDNA levels and patient age, gender, smoking status, BMI, chronic disease, colonoscopy preparation, and alcohol consumption on median cfDNA levels. The influence of cancer stage and metastasis on cfDNA levels in patients with CRC was also investigated. K2EDTA blood was collected from patients aged 50-75 years. Blood was collected at diagnosis from 889 patients with colorectal cancer, from 1056 patients needing colonoscopy (838 normal results and 218 with adenoma), and from 875 patients who, after screening, did not require a colonoscopy. Plasma was obtained by dual centrifugation at 3000 x g for 10 minutes at 20°C within 2 h of venipuncture. Plasma was stored in cryotubes at -80°C and transferred (details not provided) to a central laboratory and stored until extraction (66-3971 days total). Plasma was spiked with soybean CPP1 DNA. DNA was isolated using the QIAsymphony DSP Circulating DNA Kit and stored at -80°C. CPP1, a B-cell specific VDJ rearranged IgH, and a region of Chromosome 3 were quantified by ddPCR. cfDNA concentration was based on number of copies of Chromosome 3 detected.  The extraction efficiency was calculated based on the percent of spiked-in CPP1 recovered. Specimens were considered to have lymphocyte contamination if the B-cell specific VDJ rearrangement was amplified.

Summary of Findings

Three specimens were excluded from analysis: two due to amplification failure and one due to the detection of lymphocyte DNA. Plasma stored for ≥5 years had significantly lower levels of cfDNA than plasma stored for <5 years (P<0.01). The cfDNA yield progressively increased with patient age in patients with CRC with significant differences observed between each group when patient age was binned by decade (P<0.01, all). When only patients who did not undergo colonoscopy were examined, a significant effect of patient age was only observed in patients ≥67 years versus <67 years (P<0.001). Multivariate regression analysis showed elevated cfDNA levels were associated with undergoing colonoscopy preparation (P<0.001), patient age (P<0.001), BMI (P<0.001), and increased number of chronic diseases (P<0.001) as well as diagnosis with diabetes (P<0.001), heart disease (P<0.001), hypertension (P<0.001), IBD (P=0.007), pulmonary disease (P=0.002), or rheumatoid arthritis (P=0.022). Reduced cfDNA levels were associated with smoking (P<0.001). There was a non-significant trend toward higher cfDNA levels in males than females but there was no effect of number of units of alcohol consumed per week. Further analysis revealed significantly higher cfDNA yield in patients with each additional chronic disease from 0-4 (P<0.001, all). Patients with CRC had significantly higher cfDNA levels than those without cancer (P=0.015) but, when broken down by cancer stage, the difference was only significant for those with stage IV CRC (P<0.001). cfDNA levels were higher in patients with metastatic CRC than those without metastasis (P<0.001) and increased with tumor size (P=0.028). Overall survival was negatively associated with cfDNA levels >90% of the age-stratified reference after normalization for age, gender, BMI, smoking status, alcohol consumption, chronic diseases and CRC stage. In patients without cancer, overall survival was also negatively associated with patient age, smoking, and presence of three or more chronic diseases. In patients with CRC, overall survival was negatively associated with stage III or IV disease and patient age.

  • Biospecimens

    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    Diabetes Type 2
    Irritable Bowel Syndrome
    Cardiovascular Disease
    Rheumatoid Arthritis
    Hypertension
    NeoplasticBenign
    NeoplasticCarcinoma
    Not specified
  • Platforms

    DNADigital PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Adenoma
    CRC
    Diabetes
    Heart disease
    Hypertension
    IBD
    Non-cancer
    Pulmonary disease
    Rheumatoid arthritis
    PreaquisitionNon-invasive procedure type
    Colonoscopy preparation
    No colonoscopy preparation
    PreaquisitionOther drugs
    0 units alcohol/week
    1-7 units alcohol/week
    15-21 units alcohol/week
    8-14 units alcohol/week
    >21 units alcohol/week
    Never smoker
    Previous smoker
    Smoker
    PreaquisitionPatient age
    50-60 years
    60-70 years
    70-80 years
    <50 years
    <67 years
    >67 years
    PreaquisitionPatient body mass index
    20-25
    25-30
    35-40
    <20
    >40
    PreaquisitionPatient gender
    Female
    Male
    PreaquisitionPrognostic factor
    Metastasis
    No metastasis
    Stage I CRC
    Stage II CRC
    Stage III CRC
    Stage IV CRC
    StorageStorage duration
    <5 years
    ≥5 years